<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: We tested whether <z:chebi fb="11" ids="49575">diazepam</z:chebi>, a <z:chebi fb="3" ids="16865">GABA</z:chebi>-ergic drug that also inhibits brain nitric monoxide formation, improves <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001297'>stroke</z:hpo> prognosis </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: 880 patients, randomized within 12 h of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001297'>stroke</z:hpo>, received <z:chebi fb="11" ids="49575">diazepam</z:chebi> 10 mg or placebo by rectiole, as soon as possible, followed by 10-mg tablets twice daily for 3 days </plain></SENT>
<SENT sid="2" pm="."><plain>Primary outcome was independence (Rankin score &lt;3) at 3 months; secondary outcome was complete recovery (Barthel index &gt;or=95 or Rankin score &lt;or=1) </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Intention-to-treat analyses on <z:hpo ids='HP_0000001'>all</z:hpo> 849 patients with full follow-up (50.4% on <z:chebi fb="11" ids="49575">diazepam</z:chebi>): odds ratio (OR) 1.14, 95% CI 0.87-1.49 for primary endpoint, and an OR of 1.26 (0.90-1.76) for complete recovery, both favoring <z:chebi fb="11" ids="49575">diazepam</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>Adjusted analyses for <z:hpo ids='HP_0000001'>all</z:hpo> <z:hpo ids='HP_0001297'>stroke</z:hpo> patients (843): OR 1.20 (0.87-1.65), and 1.25 (0.89-1.74), respectively, and for <z:hpo ids='HP_0000001'>all</z:hpo> <z:mpath ids='MPATH_124'>infarct</z:mpath> patients (748): OR 1.31 (0.93-1.85), and 1.46 (1.02-2.09; p=0.037), respectively </plain></SENT>
<SENT sid="5" pm="."><plain>Analyses restricted to cardioembolic <z:mpath ids='MPATH_124'>infarct</z:mpath> patients (200) showed treatment benefit for the primary outcome: OR 2.26, 95% CI 1.07-4.76, p=0.032, and complete recovery: OR 2.65, 95% CI 1.06-6.59, p=0.037 </plain></SENT>
<SENT sid="6" pm="."><plain>About one third of <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> patients had 'any adverse event', without any difference between treatment groups </plain></SENT>
<SENT sid="7" pm="."><plain>In 95 <z:hpo ids='HP_0001342'>intracerebral hemorrhage</z:hpo> patients, frequency of <z:hpo ids='HP_0002090'>pneumonia</z:hpo> and <z:hpo ids='HP_0011420'>death</z:hpo> were higher in the <z:chebi fb="11" ids="49575">diazepam</z:chebi> group than in the placebo group: 35 and 10%, 22 and 12%, respectively </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Although point estimates favored <z:chebi fb="11" ids="49575">diazepam</z:chebi> treatment in various analyses, our data did not confirm our primary hypothesis </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="11" ids="49575">Diazepam</z:chebi> treatment seems beneficial in cardioembolic <z:mpath ids='MPATH_124'>infarct</z:mpath> patients, is safe in <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo>, but may better be avoided in <z:hpo ids='HP_0001342'>intracerebral hemorrhage</z:hpo> </plain></SENT>
</text></document>